What Бруфен ретард Treats: Main Uses and Benefits

Бруфен ретард is commonly used for symptomatic relief in situations involving pain, inflammation, and fever. The prolonged-release action supports the patient by providing sustained comfort and helping to manage the discomfort associated with inflammatory and pain-related conditions.

Therapeutic Scope and Sustained Relief

This medication is commonly used to help ease the persistent joint stiffness, localized swelling, and pain related to chronic inflammatory states, such as rheumatoid arthritis and osteoarthritis. It is applied across domains where additional symptomatic support is needed for both chronic and acute symptoms. The prolonged-release formulation supports the patient during difficult episodes by easing distress and may assist with maintaining functional stability throughout the day and night.

The medicine is applied in addressing the painful swelling and functional strain associated with soft tissue injuries like sprains, strains, and various episodic pain syndromes including headache, menstrual cramps (primary dysmenorrhoea), and toothache. Furthermore, it contributes to easing symptoms related to systemic imbalance, such as elevated body temperature (fever) and generalized body aches.

“It is applied during phases when symptoms become more noticeable, offering symptomatic relief that helps patients cope more steadily with symptom fluctuations.”

Quick Fact: Relief for Chronic Discomfort The prolonged-release mechanism is relevant in contexts marked by increased discomfort (e.g., chronic arthritis) by aiming to provide sustained relief, especially during rest or overnight.

Regulatory References

1. NIH MedlinePlus Drug Information

Eligibility for Brufen Retard (Ibuprofen 800mg Prolonged-Release)

Brufen Retard (Ibuprofen 800mg prolonged-release) is approved for use in adults and adolescents over 12 years of age who do not have documented contraindications. Eligibility is strictly defined by regulatory guidelines, focusing on absolute exclusions and populations requiring conditional use.

---

Absolute Contraindications (Must Not Use)

Use is prohibited if a patient has:

• Hypersensitivity to Ibuprofen, Aspirin, or other NSAIDs.
• Active gastrointestinal bleeding or ulceration or a history of recurrent peptic ulcer disease.
• Severe organ failure (severe heart failure [NYHA Class IV], severe hepatic failure, or severe renal failure).
• Last trimester of pregnancy.

---

Populations Requiring Special Caution

• The Elderly: Use the lowest effective dose for the shortest possible duration and monitor closely for gastrointestinal complications.
• Mild to Moderate Organ Impairment: Requires careful individual assessment for patients with mild to moderate renal or hepatic dysfunction.
• Pregnancy: Contraindicated in the last trimester; use in the first six months requires careful consideration of benefit versus risk.
• Children under 12 years are generally excluded from using the 800mg prolonged-release formulation.

The official regulatory profile for Бруфен ретард (Ibuprofen, an NSAID) documents several critical interaction domains, defining formal restrictions and requirements for co-administration. Co-administration with other NSAIDs (including COX-2 inhibitors) is formally contraindicated due to the significantly increased risk of serious gastrointestinal adverse events. Use with high-dose Acetylsalicylic Acid for pain relief is also generally avoided, and Alcohol ingestion is explicitly noted to increase the risk of severe stomach bleeding.

Ibuprofen may cause a pharmacokinetic interaction by reducing the renal clearance of certain narrow-therapeutic-index medicines. This mechanism leads to a potential increase in plasma concentration and risk of toxicity for substances like Lithium and Methotrexate. A similar risk is noted for Cardiac Glycosides.

Documentation highlights pharmacodynamic risks where ibuprofen enhances the effects of Anticoagulants (Warfarin), Antiplatelet Agents, and Oral Corticosteroids, leading to an additive risk of serious bleeding. Conversely, ibuprofen may blunt the efficacy of Antihypertensives (ACE inhibitors, ARBs) and Diuretics.

To mitigate interference with the antiplatelet effect of low-dose, immediate-release Aspirin, regulatory guidance specifies a mandatory timing separation of at least 30 minutes after or 8 hours before the ibuprofen dose. Official labeling notes that the Elderly and patients with pre-existing renal or cardiac impairment are at a heightened risk of interaction-related complications.

The mechanism of Бруфен ретард is centered on the biological process of enzyme inhibition to modulate signaling pathways associated with inflammatory and thermoregulatory responses.

Targeting the Cyclooxygenase Pathway

The primary action involves the non-selective and reversible inhibition of the Cyclooxygenase ( COX) enzymes ( COX-1 and COX-2). This step blocks the conversion of arachidonic acid, a precursor for key signaling molecules, thus modifying early molecular steps that shape systemic physiological outcomes.

Suppressing Key Inflammatory and Pain Mediators

By inhibiting the COX enzymes, the drug fundamentally suppresses the synthesis of prostaglandins, particularly PGE2. This action results in a decrease in the concentration of these mediators, influencing fluid accumulation and peripheral pain receptor sensitization.

Regulating Central Thermoregulation

The mechanism extends to the central nervous system where it acts within the hypothalamus, the body's thermoregulatory center. Inhibition of PGE2 synthesis here influences the processes driven by these signaling patterns, affecting the body's thermoregulatory set-point and contributing to its physiological adjustment.

How to Use Бруфен ретард: Administration Guidelines

Бруфен ретард is administered exclusively via the oral route as a prolonged-release tablet containing 800 mg of ibuprofen. The instructions for use are determined by the requirements of the sustained-release formulation and general NSAID administration principles.

---

Dosing and Schedule

The standard adult daily dose is generally 1600 mg, corresponding to two 800 mg tablets, taken as a single administration once daily. This single dose is typically taken in the early evening, before bedtime, to utilize the prolonged-release properties effectively. For severe symptoms, the total daily dose may be increased to a maximum of 2400 mg (three 800 mg tablets), in which case the dose must be divided into morning and evening administrations. Treatment should always commence using the lowest effective dose for the shortest possible duration.

Administration Instructions

To preserve the integrity of the controlled-release mechanism, the tablets must be swallowed whole with at least half a glass of water. They should not be chewed, broken, crushed, or sucked on. While the medicine can be taken without reference to meals, patients experiencing stomach sensitivity are advised to take the dose with food.

Population Rules and Missed Doses

Бруфен ретард is not recommended for use in children under the age of 12 years. For older adults, the general principle of using the lowest effective dose for the shortest duration applies. If a dose is missed, it is recommended not to take a double dose to compensate, but instead to resume the usual single-dose schedule at the next scheduled time.

Research Evidence / Overview of Studies for Бруфен ретард

---

Evidence for use in Chronic Inflammatory Conditions

Research has explored this prolonged-release formulation in conditions characterized by functional limitations, such as osteoarthritis and rheumatoid arthritis. Studies monitored outcomes related to physical symptoms, including measures of joint tenderness and stiffness, and patient reports describing activity level. Observational research, conducted in general practice settings, described the evolution of day and night pain scores over defined time intervals, such as a four-week course of treatment.

Studies monitored key patient-reported outcomes related to perceived discomfort. The findings from these studies apply only to the patient populations studied, and the evidence base includes both controlled trials and observational settings. There is limited information for long-term outcomes, as many initial trials focus on short-term symptom changes.

---

Evidence for use in Acute and Episodic Pain States

Research examined this formulation in conditions involving periods of heightened symptoms, such as acute or disruptive episodes like headache, menstrual cramps (primary dysmenorrhoea), and post-operative pain. This evidence comes from short-term Randomized Controlled Trials (RCTs), often compared to an inactive substance (placebo). Outcomes related to physical discomfort were monitored, including how symptoms evolved in the observed populations by measuring pain intensity difference scores over short, defined time intervals (e.g., 6 to 12 hours).

Comparative evidence is currently lacking regarding differences in outcomes between the prolonged-release form and standard, immediate-release forms for single episodes of acute pain. Research has explored whether doses above a certain level were evaluated for differences in measured outcomes for mild-to-moderate acute pain, and findings contribute to the broader evidence landscape.

---

Long-Term Studies and What is Still Uncertain

Long-term epidemiological analyses, frequently cited in regulatory reviews, examined outcomes such as the incidence of cardiovascular thrombotic events (like heart attack or stroke). Findings describe patterns related to a small increased risk, observed at doses at or above 2400 mg per day. Data from these settings noted an absence of consistent increased risk with lower doses, such as up to 1200 mg per day.

Evidence is limited for the utility of the prolonged-release formulation when compared directly to the standard tablet for acute, short-lived pain episodes. For patients taking low-dose aspirin, some laboratory data suggest that the anti-clotting effects may be reduced by ibuprofen, but clinical data findings were mixed, and certainty remains low regarding whether this is a meaningful long-term concern for occasional use.

Key Studies & References

1. High-dose ibuprofen (≥2400mg/day): small increase in cardiovascular risk (Regulatory Statement based on Meta-analysis)
2. Use of ibuprofen sustained release for treating osteoarthritic pain: a prospective observational study (Example of a chronic pain outcomes study)
3. Public Assessment Report for paediatric studies submitted in accordance with Article 45 of Regulation (EC) No1901/2006 (Ibuprofen in children/adolescents)

Common questions about Бруфен ретард (FAQ)

Q: Does Brufen retard contain Ibuprofen?

Yes, the active substance in this medicine is Ibuprofen, which is classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID). Official documentation confirms Ibuprofen as the primary active ingredient.

Q: Are there requirements for use in people with kidney problems?

Official documents state that use is generally avoided in patients with severe kidney disease, unless the expected benefits outweigh the potential risks. If the medicine is used in these cases, these patients require monitoring for signs of kidney function deterioration.

Q: Can Brufen retard be taken by people with high blood pressure?

Official information notes that NSAIDs like Ibuprofen can lead to the new onset or worsening of pre-existing high blood pressure. Therefore, caution is recommended when the medicine is used in patients who have this condition.

Q: Does Brufen retard affect heart function?

Regulatory warnings highlight an increased risk of serious cardiovascular thrombotic events, which are described as events like myocardial infarction and stroke. This risk may occur early in treatment and may increase with the duration of use.

Q: What is the general recommendation for duration of treatment?

The official recommendation across regulatory sources is that the medicine should be used at the lowest effective dosage for the shortest possible duration of time. This guidance is provided to minimize the potential risk of adverse reactions.

Q: What is shown in the official documents about its safety?

Official documentation emphasizes potential risks related to serious gastrointestinal adverse reactions, such as bleeding and ulcers, as well as the risk of cardiovascular thrombotic events. These risks are often associated with higher dosages and longer duration of use of the drug.

Q: Is there any information about long-term use?

Long-term use is not recommended and is associated with an increased risk of serious adverse reactions, including gastrointestinal and cardiovascular events. Official guidelines consistently advise for the shortest possible duration of treatment.

Q: Can Brufen retard be used for headache?

Medicines containing Ibuprofen are listed in official documents for the temporary relief of pain and/or inflammation associated with various types of headache.

Q: Can it be used for chronic pain?

Ibuprofen is listed in official documentation for the management of symptoms associated with certain chronic conditions, such as ankylosing spondylitis and osteoarthritis.

Q: Are there known interactions with alcohol?

Official information explicitly states that consuming alcohol during treatment increases the risk of serious bleeding in the stomach or intestines.

Q: What are the general side effects that can be expected?

Common side effects listed in official documentation include gastrointestinal disturbances such as indigestion or stomach aches, nausea, vomiting, headache, and dizziness.

Q: Can it cause stomach problems?

Yes, the medicine can cause stomach problems. Regulatory warnings include the risk of serious gastrointestinal adverse reactions such as bleeding, ulcers, and perforation.

Q: Can it cause drowsiness or affect driving?

Official product information indicates that the medicine may cause dizziness or drowsiness. If these effects are experienced, regulatory guidelines indicate that individuals should refrain from driving or operating heavy machinery.

Q: What are the signs of an allergic reaction?

Signs of a serious allergic reaction may include hives, difficulty breathing (shortness of breath, wheezing), a widespread rash, swelling of the face or throat, or sudden collapse.

Q: Why is a prescription required for some dosages?

Regulatory bodies typically classify higher dosages of Ibuprofen as prescription-only medicines (Rx). This requirement is due to the increased strength and potential for adverse reactions at higher doses, which necessitates medical supervision.

Q: Are there any restrictions on food or drinks when taking it?

Official information contains a specific warning regarding the use of alcohol due to the increased risk of stomach bleeding. Additionally, taking the medicine with food may be recommended to reduce stomach sensitivity.

Q: Is there a risk of addiction to this medicine?

Ibuprofen is generally not classified as a controlled substance with a high risk of abuse or addiction under major international regulatory systems.

Q: How is its effect on the liver described in official sources?

Official information notes that borderline elevations in liver enzyme tests have been observed. In rare cases, serious liver reactions have been reported, including jaundice and liver failure.

Q: Are there studies that compare the 'retard' form with ordinary tablets?

The development of the prolonged-release ('retard') form was aimed at reducing the dosing frequency to once daily. Studies focus on ensuring it achieves equivalent bioavailability (absorption) compared to conventional immediate-release tablets.

Q: What is the information on its use during breastfeeding?

Due to extremely low levels of Ibuprofen found in breast milk, official sources describe it as an analgesic or anti-inflammatory agent that may be used by nursing mothers.

Q: Does Brufen retard affect the results of laboratory tests?

Official information contains warnings that Ibuprofen may interfere with the results of certain laboratory tests. This could potentially lead to false-positive results for specific drug screenings in urine.

Q: Can it cause dizziness?

Yes, dizziness is listed among the common side effects detailed in the official documentation.

Q: How is the quality of this medicine controlled according to regulatory bodies?

The quality of the medicine is controlled according to strict regulatory guidelines (such as ICH Q3D and USP standards). These guidelines set limits for impurities and require testing to ensure the product's purity and safety.

Storage & Disposal Map: Official Regulatory Information

The storage and disposal requirements for Brufen Retard are defined by regulatory authorities to ensure product stability and safety.

Storage Conditions	Regulatory Requirement
Temperature Limit	Store at a temperature not exceeding 25 C.
Packaging	Keep the medicine in its original package for protection.
Child Safety	Must be stored out of the sight and reach of children.
Disposal Prohibition	Do not dispose of via household waste or down the drain.

Adherence to the maximum 25 C storage temperature is required for the stability of the prolonged-release formulation. For disposal, the regulatory instruction is to return unused or expired product to a pharmacist or follow local collection schemes, thereby ensuring environmentally safe destruction.